Hughes-Wilson Alexandra 4
4 · Mereo BioPharma Group plc · Filed Sep 13, 2024
Insider Transaction Report
Form 4
Hughes-Wilson Alexandra
See Remarks
Transactions
- Exercise/Conversion
Performance Based Restricted Stock Unit
2024-09-11−40,000→ 0 totalExercise: $0.00From: 2024-09-11Exp: 2025-01-25→ American Depository Shares (40,000 underlying) - Exercise/Conversion
American Depositary Shares representing Ordinary Shares
2024-09-11+40,000→ 74,548 total - Exercise/Conversion
American Depositary Shares representing Ordinary Shares
2024-09-11$1.01/sh+75,000$75,750→ 242,881 total - Exercise/Conversion
American Depositary Shares representing Ordinary Shares
2024-09-11$1.40/sh+93,333$130,666→ 167,881 total - Exercise/Conversion
Share Options (Right to buy)
2024-09-11$1.40/sh−93,333$130,666→ 0 totalExercise: $1.40Exp: 2032-01-14→ American Depository Shares (93,333 underlying) - Exercise/Conversion
Share Options (Right to buy)
2024-09-11$1.01/sh−75,000$75,750→ 0 totalExercise: $1.01Exp: 2033-01-25→ American Depository Shares (75,000 underlying)
Footnotes (4)
- [F1]Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
- [F2]Represents performance-based restricted stock unit earned under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period.
- [F3]160,000 options were issued on 01/14/2022 and 25% of the shares underlying this award became exercisable on January 14, 2023, with the remainder vesting in equal monthly installments thereafter.
- [F4]240,000 options were issued on 01/25/2023 and 25% of the shares underlying this award became exercisable on January 25, 2024, with the remainder vesting in equal monthly installments thereafter.